NEW YORK, Jan. 15, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Sarepta Therapeutics Inc. ("Sarepta" or "the Company") (Nasdaq: SRPT). Such investors are advised to contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz at email@example.com or 212-697-6484.
This investigation concerns whether Sarepta and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act").
On January 15, 2016, pre-market, the U.S. Food and Drug Administration (the "FDA") published a statements on its web site the FDA Briefing Information (the "FDA Briefing Information") by an agency advisory committee to review the New Drug Application filed by Sarepta Therapeutics, Inc. for eteplirsen as a treatment for Duchenne muscular dystrophy. The agency's internal review of eteplirsen stated, in part, that "[a]lthough FDA is prepared to be flexible with respect to a devastating illness with no treatment options, we cannot approve drugs for which substantial evidence of effectiveness has not been established."
Following this news, Sarepta stock has fallen as much as $18.25 per share, or nearly 58%, to $13.38 on January 15, 2016 during intraday trading.
If you are aware of any facts relating to this investigation, or purchased shares of Sarepta, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!srpt/lkx3u. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | email@example.com
SOURCE Bronstein, Gewirtz & Grossman, LLC